Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 102

1.

Malignant pericytes expressing GT198 give rise to tumor cells through angiogenesis.

Zhang L, Wang Y, Rashid MH, Liu M, Angara K, Mivechi NF, Maihle NJ, Arbab AS, Ko L.

Oncotarget. 2017 May 25;8(31):51591-51607. doi: 10.18632/oncotarget.18196. eCollection 2017 Aug 1.

2.

Enhancing diversity in the hematology biomedical research workforce: A mentoring program to improve the odds of career success for early stage investigators.

Pace BS, Makala LH, Sarkar R, Liu L, Takezaki M, Mohandas N, Dixon G, Werner EM, Jeffe DB, Rice TK, Maihle NJ, González J.

Am J Hematol. 2017 Dec;92(12):1275-1279. doi: 10.1002/ajh.24899. Epub 2017 Sep 25. No abstract available.

PMID:
28857249
3.

Metformin alters DNA methylation genome-wide via the H19/SAHH axis.

Zhong T, Men Y, Lu L, Geng T, Zhou J, Mitsuhashi A, Shozu M, Maihle NJ, Carmichael GG, Taylor HS, Huang Y.

Oncogene. 2017 Apr 27;36(17):2345-2354. doi: 10.1038/onc.2016.391. Epub 2016 Oct 24.

4.

A Perspective on Promoting Diversity in the Biomedical Research Workforce: The National Heart, Lung, and Blood Institute's PRIDE Program.

Boyington JE, Maihle NJ, Rice TK, Gonzalez JE, Hess CA, Makala LH, Jeffe DB, Ogedegbe G, Rao DC, Dávila-Román VG, Pace BS, Jean-Louis G, Boutjdir M.

Ethn Dis. 2016 Jul 21;26(3):379-86. doi: 10.18865/ed.26.3.379.

5.

GT198 Expression Defines Mutant Tumor Stroma in Human Breast Cancer.

Yang Z, Peng M, Cheng L, Jones K, Maihle NJ, Mivechi NF, Ko L.

Am J Pathol. 2016 May;186(5):1340-50. doi: 10.1016/j.ajpath.2016.01.006. Epub 2016 Mar 18.

6.

A Federated Network for Translational Cancer Research Using Clinical Data and Biospecimens.

Jacobson RS, Becich MJ, Bollag RJ, Chavan G, Corrigan J, Dhir R, Feldman MD, Gaudioso C, Legowski E, Maihle NJ, Mitchell K, Murphy M, Sakthivel M, Tseytlin E, Weaver J.

Cancer Res. 2015 Dec 15;75(24):5194-201. doi: 10.1158/0008-5472.CAN-15-1973. Review.

7.

Reduced expression of the epidermal growth factor signaling system in preeclampsia.

Armant DR, Fritz R, Kilburn BA, Kim YM, Nien JK, Maihle NJ, Romero R, Leach RE.

Placenta. 2015 Mar;36(3):270-8. doi: 10.1016/j.placenta.2014.12.006. Epub 2014 Dec 27.

8.

Shedding of soluble epidermal growth factor receptor (sEGFR) is mediated by a metalloprotease/fibronectin/integrin axis and inhibited by cetuximab.

Wilken JA, Perez-Torres M, Nieves-Alicea R, Cora EM, Christensen TA, Baron AT, Maihle NJ.

Biochemistry. 2013 Jul 2;52(26):4531-40. doi: 10.1021/bi400437d. Epub 2013 Jun 21.

PMID:
23731208
9.

Transient anabolic effects accompany epidermal growth factor receptor signal activation in articular cartilage in vivo.

Shepard JB, Jeong JW, Maihle NJ, O'Brien S, Dealy CN.

Arthritis Res Ther. 2013;15(3):R60.

10.

A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study.

Leslie KK, Sill MW, Fischer E, Darcy KM, Mannel RS, Tewari KS, Hanjani P, Wilken JA, Baron AT, Godwin AK, Schilder RJ, Singh M, Maihle NJ.

Gynecol Oncol. 2013 Jun;129(3):486-94. doi: 10.1016/j.ygyno.2013.02.019. Epub 2013 Feb 21.

11.

Soluble Human Epidermal Growth Factor Receptor 2 (sHER2) as a Potential Risk Assessment, Screening, and Diagnostic Biomarker of Lung Adenocarcinoma.

Cosentino-Boehm AL, Lafky JM, Greenwood TM, Kimbler KD, Buenafe MC, Wang Y, Branscum AJ, Yang P, Maihle NJ, Baron AT.

Diagnostics (Basel). 2013 Jan 14;3(1):13-32. doi: 10.3390/diagnostics3010013.

12.

Lin28 regulates BMP4 and functions with Oct4 to affect ovarian tumor microenvironment.

Ma W, Ma J, Xu J, Qiao C, Branscum A, Cardenas A, Baron AT, Schwartz P, Maihle NJ, Huang Y.

Cell Cycle. 2013 Jan 1;12(1):88-97. doi: 10.4161/cc.23028. Epub 2012 Dec 19.

13.

Lin28 regulates HER2 and promotes malignancy through multiple mechanisms.

Feng C, Neumeister V, Ma W, Xu J, Lu L, Bordeaux J, Maihle NJ, Rimm DL, Huang Y.

Cell Cycle. 2012 Jul 1;11(13):2486-94. doi: 10.4161/cc.20893. Epub 2012 Jul 1.

PMID:
22713243
14.

EGFR/HER-targeted therapeutics in ovarian cancer.

Wilken JA, Badri T, Cross S, Raji R, Santin AD, Schwartz P, Branscum AJ, Baron AT, Sakhitab AI, Maihle NJ.

Future Med Chem. 2012 Mar;4(4):447-69. doi: 10.4155/fmc.12.11. Review.

15.

The epidermal growth factor receptor conundrum.

Wilken JA, Baron AT, Maihle NJ.

Cancer. 2011 Jun 1;117(11):2358-60. doi: 10.1002/cncr.25805. Epub 2010 Dec 14. No abstract available.

16.

Identification of immunoreactive regions of homology between soluble epidermal growth factor receptor and α5-integrin.

Wilken JA, Baron AT, Foty RA, McCormick DJ, Maihle NJ.

Biochemistry. 2011 May 24;50(20):4309-21. doi: 10.1021/bi200126j. Epub 2011 Apr 27.

17.

Primary trastuzumab resistance: new tricks for an old drug.

Wilken JA, Maihle NJ.

Ann N Y Acad Sci. 2010 Oct;1210:53-65. doi: 10.1111/j.1749-6632.2010.05782.x.

18.

EGFR isoforms and gene regulation in human endometrial cancer cells.

Albitar L, Pickett G, Morgan M, Wilken JA, Maihle NJ, Leslie KK.

Mol Cancer. 2010 Jun 25;9:166. doi: 10.1186/1476-4598-9-166.

19.

Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics.

Wilken JA, Webster KT, Maihle NJ.

J Ovarian Res. 2010 Mar 27;3:7. doi: 10.1186/1757-2215-3-7.

20.

Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer.

Peng S, Maihle NJ, Huang Y.

Oncogene. 2010 Apr 8;29(14):2153-9. doi: 10.1038/onc.2009.500. Epub 2010 Jan 25.

PMID:
20101213

Supplemental Content

Loading ...
Support Center